Komatsuda Hiroki, Sim Edward S, Uppaluri Ravindra
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.
Trends Cancer. 2025 Jun;11(6):496-498. doi: 10.1016/j.trecan.2025.04.013. Epub 2025 May 6.
Whether combination neoadjuvant immunotherapy can enhance response in patients with head and neck cancer remains unclear. Recently, Li et al. demonstrated improved responses with neoadjuvant anti-PD-1+CTLA-4 or anti-PD-1+LAG-3 compared with anti-PD-1 monotherapy. These combination strategies act via different mechanisms with distinct biomarkers of response, highlighting the potential for personalized neoadjuvant immunotherapy approaches.
联合新辅助免疫疗法能否增强头颈癌患者的反应仍不清楚。最近，李等人证明，与抗PD-1单药治疗相比，新辅助抗PD-1+CTLA-4或抗PD-1+LAG-3的反应有所改善。这些联合策略通过不同机制起作用，具有不同的反应生物标志物，凸显了个性化新辅助免疫疗法的潜力。
